Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide
This article was originally published in The Pink Sheet Daily
Executive Summary
Once-a-day here to stay? With once-weekly taspoglutide just officially rejected by Roche and long-lasting Bydureon delayed on safety, Zealand CEO talks up the virtues of QD GLP-1 analogs.
You may also be interested in...
Pressure Mounts For Amylin As Bydureon PDUFA Approaches
With declining sales of Byetta, Amylin has staked its near-term future on the performance of Bydureon, a long-acting formulation of the active ingredient in Byetta.
With Lilly Out, Amylin’s Future Is Tied To Bydureon
With the unwinding of its once-lucrative nine-year partnership with Eli Lilly, Amylin Pharmaceuticals now carries all the risk – and all the reward – of its exenatide franchise for diabetes. With sole ownership of its exenatide franchise, Amlyin now has the freedom to seek a lucrative partnership or opt to sell the company outright to a large pharma seeking an edge in a growing diabetes market.
Lixisenatide Gains Evidence Of A Weight Loss Benefit
Sanofi/Zealand's GLP-1 agonist lixisenatide continues to show promise in the latest GetGoal results, this time in type 2 diabetics inadequately controlled on sulfonylureas.